A case for gender-based approach to multiple sclerosis therapeutics-Reference-Cited by-同舟云学术

A case for gender-based approach to multiple sclerosis therapeutics

Published:2018-07 Issue: Volume:50 Page:123-134
ISSN:0091-3022
Container-title:Frontiers in Neuroendocrinology
language:en
Short-container-title:Frontiers in Neuroendocrinology

Author:

Houtchens Maria K.,Bove Riley^ORCID

Publisher

Elsevier BV

Subject

Endocrine and Autonomic Systems

Reference126 articles.

1. Recent use of oral contraceptives and the risk of multiple sclerosis;Alonso;Arch. Neurol.,2005

2. Fingolimod-associated amenorrhea: a report of three cases;Alroughani;Mult. Scler,2014

3. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era;Alroughani;Neurology,2018

4. Avonex ® FDA Label (interferon β-1a) [online]. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2007/103628s5115lbl.pdf (accessed June 1).

5. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods;Barth;Front. Neurosci.,2015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study;Journal of Women's Health;2024-04-01

2. Sex impacts treatment decisions in multiple sclerosis;Journal of Neurology;2024-03-05

3. Women’s Health and Pregnancy in Multiple Sclerosis;Neurologic Clinics;2024-02

4. MS care: integrating advanced therapies and holistic management;Frontiers in Neurology;2024-01-30

5. Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study;The Lancet Regional Health - Americas;2024-01